# Dupixent (dupilumab) litigation

> Educational mass tort overview from DrugsMonitor.com. Not legal or medical advice.

**Canonical URL:** https://drugsmonitor.com/case/dupixent-dupilumab-lawsuit
**Last updated:** 2026-06-11

## Key facts

- **Matter:** Dupixent (dupilumab)
- **Status:** Emerging
- **Scope:** United States — national overview
- **Drug safety page:** https://drugsmonitor.com/drug-info/dupixent-dupilumab-lawsuit

## Overview

Dupilumab (Dupixent) is a biologic used for atopic dermatitis, asthma, and other conditions. Some litigation and regulatory discussion have focused on ocular surface disease—including keratitis and vision-related harms in a subset of patients—and whether labeling and monitoring were adequate.

### Alleged harms

Complaints in public filings include keratitis, ulceration, and vision loss requiring specialist care. Manufacturers dispute general causation and emphasize labeled risks.

### Records that help establish timelines

Ophthalmology notes, imaging, medication start/stop dates, and prescribing history for dupilumab are often central to individualized review.

---

*DrugsMonitor.com is not a law firm. For medical decisions consult a licensed clinician; for legal decisions consult a qualified attorney.*